Abstract：
UNASSIGNED: In this article, we discuss menstrual migraine (MM), which can be categorized as menstrually related migraine (MRM) or pure menstrual migraine (PMM). MM attacks are often longer, more severe, and harder to treat than other migraine attacks. Appropriate treatment strategies include acute treatment, short term preventive treatment, and daily preventive treatment, depending on the patient\'s pattern of migraine and occurrence of migraine outside the menstrual period.
UNASSIGNED: A PubMed, Cochrane Library, Medline, and Ovid search from inception to October 2022 provided articles relating to MM pathophysiology and treatment.
UNASSIGNED: In patients for whom standard acute therapy is inadequate, short term or daily preventive treatment should be considered. Patients with PMM may be adequately managed with short term preventive treatment started 2 days prior to the onset of migraine and continued for 5-6 days. Frovatriptan is the mainstay of short-term prevention. Patients who experience additional attacks outside the menstrual period may benefit from daily preventive treatment. Estrogen-containing contraceptive treatment may be effective in appropriately selected patients. Emerging research on the pathophysiology of MM indicates that oxytocin agonists and CGRP antagonists may prove to be effective treatment options.
UNASSIGNED: A PubMed, Cochrane Library, Medline, and Ovid search from inception to October 2022 provided articles relating to MM pathophysiology and treatment.
UNASSIGNED: In patients for whom standard acute therapy is inadequate, short term or daily preventive treatment should be considered. Patients with PMM may be adequately managed with short term preventive treatment started 2 days prior to the onset of migraine and continued for 5-6 days. Frovatriptan is the mainstay of short-term prevention. Patients who experience additional attacks outside the menstrual period may benefit from daily preventive treatment. Estrogen-containing contraceptive treatment may be effective in appropriately selected patients. Emerging research on the pathophysiology of MM indicates that oxytocin agonists and CGRP antagonists may prove to be effective treatment options.
摘要：
■在本文中，我们讨论月经偏头痛（MM），可分为经期相关偏头痛（MRM）或纯经期偏头痛（PMM）。MM攻击时间往往较长,更严重,比其他偏头痛发作更难治疗。适当的治疗策略包括急性治疗，短期预防性治疗,和日常预防治疗，取决于患者的偏头痛模式和月经期以外的偏头痛的发生。
■APubMed,科克伦图书馆,Medline,从开始到2022年10月的Ovid搜索提供了有关MM病理生理学和治疗的文章。
■在标准急性治疗不足的患者中，应考虑短期或每日预防性治疗。PMM患者可以在偏头痛发作前2天开始短期预防性治疗并持续5-6天。Frovatriptan是短期预防的支柱。在月经期以外经历额外发作的患者可能会从日常预防治疗中受益。含雌激素的避孕治疗对适当选择的患者可能有效。关于MM的病理生理学的新兴研究表明催产素激动剂和CGRP拮抗剂可能被证明是有效的治疗选择。
■APubMed,科克伦图书馆,Medline,从开始到2022年10月的Ovid搜索提供了有关MM病理生理学和治疗的文章。
■在标准急性治疗不足的患者中，应考虑短期或每日预防性治疗。PMM患者可以在偏头痛发作前2天开始短期预防性治疗并持续5-6天。Frovatriptan是短期预防的支柱。在月经期以外经历额外发作的患者可能会从日常预防治疗中受益。含雌激素的避孕治疗对适当选择的患者可能有效。关于MM的病理生理学的新兴研究表明催产素激动剂和CGRP拮抗剂可能被证明是有效的治疗选择。
